Panobinostat (LBH589)

Catalog No.S1030 Synonyms: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Size Price Stock Quantity  
USD 90 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 47 Publications

11 Customer Reviews

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Panobinostat (LBH589) purchased from Selleck.

    HDACIs That Simultaneously Inhibit HDACs 1 and 6 Showed Greater Antileukemic Activities than HDACIs that Don’t at Cmax Concentrations. THP-1 cells were treated with LBH-589, PXD101, SAHA, VPA, MS-275 and MGCD0103 at Cmax concentrations for 3 h and 24 h, respectively. The cells post 3 h treatments were washed three times with complete medium and divided into two halves. One half of the cells was resuspended in complete media and cultured for up to 24 h to determine the effects of the 3 h treatments on cell proliferation and apoptosis. The other half of the cells was used to prepare whole cell lysates. Whole cell lysates from the 3 h and 24 h treatments were extracted and subjected to Western blots probed by anti-ac-tubulin or –b-actin antibody (panels A&B), or subjected to HDAC1 enzymatic assays post IP as described in the Materials and Methods (Panels C&D). The effects of the 3 h and 24 h HDACI treatments on cell proliferation, as reflected by percent decrease of live cells relative to untreated cells (panel E), and apoptosis (panel F) were determined by flow cytometry analysis as described in the Materials and Methods.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

  • Induction of DNA Damage and Bim Is Critical for HDACI-Induced Apoptosis in Pediatric AML Cells. THP-1 cells were treated with the HDACIs at Cmax concentrations for 3 (panel A) and 24 h (panel B), respectively. Whole cell lysates were extracted and subjected to Western blots probed by anti-p21, -c-Myc, -cH2AX, -Bim, or -b-actin antibody.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

    Cell death induction by LBH589 as a single agent was detected in control or MTDH knockdown Hec50co cells. After 3 days, cell death was determined by the WST-1 method.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

  • Expression of pro-/anti-apoptosis genes. Control or MTDH knockdown Hec50co cells were treated for 24 hours with vehicle control, 20 nM LBH589, 25 ng/ml TRAIL or LBH589 and TRAIL at the concentrations noted. Lysates were collected. Expression of DR4, DR5, and apoptosis related caspase-3, caspase-8, PARP-1, BID, FLIP, XIAP, Bim, MCL-1 and BCL-XL was analyzed by Western blotting.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

    Using CRISPR-Cas9 technology, ERα was silenced at the genomic level in ECC1 cells. Ishikawa, parental ECC1 cells and individual ESR1 KO ECC1 clones were treated with 20 nM LBH589 for 24 hr. Expression of ERα, PR, FOXO1, and Myc were evaluated by Western blotting. β-actin serves as a loading control.

    PLoS One, 2016, 11(2):e0148912.. Panobinostat (LBH589) purchased from Selleck.

  • Effect of panobinostat on the viability of cervical cancer cells. HeLa (A) and SiHa (B) cells were treated with increasing concentrations of panobinostat for 24, 48 and 72 h. Cell viability was determined by MTT assay. The results are presented as percentage; calculated from the reduction in cell viability at a given concentration of drug compared to the untreated control (untreated control being 100%). The IC5072h values were calculated from sigmoidal dose-response curves generated in Prism 5.0 (GraphPad). (C) Cytotoxic effects of panobinostat on HeLa and SiHa cells measured at 72 h and expressed as% cell death. Each value is the mean ± SD of three independent experiments performed in triplicates.

    Biomed Pharmacother, 2016, 84:1393-1405. Panobinostat (LBH589) purchased from Selleck.

    p53(+/+) and (/) HCT116 cells were treated with TSA (1–5 lM),LBH589 (2–5 lM), valproate (2.5–5 mM), MS-275 (20 lM) and sodium butyrate (2 mM). TAp63 expression was compared in both cell lines after 24 h of treatment. Consistent with the above data, all HDAC inhibitors failed to induce significant levels of TAp63 in p53(/) HCT116 cells.

     

     

    Biochem Bioph Res Co 2009 391, 1748-1751. Panobinostat (LBH589) purchased from Selleck.

  • Western blot analysis of Acetyl-H3 and H3. 0-10μM Panobinostat was added.

    Dr.Zhang of Tianjin Medical University. Panobinostat (LBH589) purchased from Selleck.

    HDAC inhibitors induce p63a expression (A) HCT116 cells were treated with TSA (1 lM), LBH589 (2 lM), valproate (2.5 mM), MS-275 (20 lM) and sodium butyrate(2 mM) for 24 h. Expression of p63 was assessed by Western blotting with the H129 pan-anti-p63 antibody. Although TSA and LBH589 induced p63 efficiently, valproate, MS-275 and sodium butyrate were much less efficient. The lower panel shows the actin loading control. Arrow indicates TAp63. (B) The HDAC inhibitors used in this study are shown, grouped according to their structure and with their HDAC specificity. The efficiency of TAp63 expression is shown in the last column.

     

     

    Dr. Berna S. Sayan of Leicester University. Panobinostat (LBH589) purchased from Selleck.

  • U266 and KMS-11 were treated with 20 nM panobinostat for 48 h followed by Western blot analysis. Actin served as a loading control. Nine (U266) and 3 (KMS-11) biologically independent experiments were performed. To determine the expression of PPP3CA mRNA in treated cells for 24 h, we performed relative quantification real-time PCR (n = 6). Four (U266) and 2 (KMS-11) biologically independent experiments were performed.

    JCI Insight, 2016, 1(5):e85061. Panobinostat (LBH589) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 M1u2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITCSYQxNTFyIN88US=> NUS5OVV6OC12IHS= NV\i[o9kcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MVWyOlcxOjd6NB?=
HepG2 NEHJdnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XHO|AuOTBizszN MlzoNE01KGR? MlHabY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NGPXR2kzPjdyMke4OC=>
HT29 NGn0Wo1HfW6ldHnvckBCe3OjeR?= M17OUFUxyqCwTR?= MVOyOE04OiCq MYjpcoR2[2WmIHHjeIl3[XSrb36gc4Yh[2G|cHHz[UA{KGGodHXyJFQ5yqCqwrC= M2rqeFI3PzB{N{i0
HepG2 MoC3SpVv[3Srb36gRZN{[Xl? MV[1NOKhdk1? MVuyOE04OiCq NGnUbIhqdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|IHHmeIVzKDJ2wrDoxsA> M4LnVlI3PzB{N{i0
HCC827 NHjydJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTVOU84NjVxMUCgcm0> MlL6O|LDqGh? M1HjfWROW09? NVjvfXl{\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= M2r6XVI3Pjd3NEi0
A549  NGTsWHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XnXFExNzF3L{KwJI5O MV[3NuKhcA>? NULreodRTE2VTx?= MYnlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? NXi5dVJKOjZ4N{W0PFQ>
NCI-H460  M2fIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vySFExNzJyL{OwJI5O NFHDfok4OsLiaB?= MWfEUXNQ MoXT[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ? Mn\kNlY3PzV2OES=
J89GFP MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;EdGE3TE2VT9Mg M2\NeGVEPTB;NEmuPFUhyrFiMUKuOlUhdk1? MoPhNlY2PjN3Nki=
THP89GFP MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2flPWROW00EoB?= NVHwZ2lJTUN3ME2xPU4{PCEEsTC2MlQ{KG6P MoHENlY2PjN3Nki=
SK-NEP-1 NI\YT|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jrcVAvODIkgKOxNE4xKM7:TR?= NVq3c3F1OjRiaB?= MormSG1UV8Li MXrJR|UxRTd4LkO0JI5O M3\pbFI3OTd4MkG5
G401 M4PEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjHUWYxNjBz4pETNVAvOCEQvF2= MoTSNlQhcA>? Ml3ESG1UV8Li NVvpV|ljUUN3ME2xOFMvODJibl2= MnTuNlYyPzZ{MUm=
SK-NEP-1 MoS4R4VtdCCYaXHibYxqfHliQYPzZZk> M3jtZVUxKG6P MYmx5qCUPCCm MVzEUXNQyqB? M{DPUZJm\HWlZYOgZ4VtdCC|dYL2bZZidCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? MnP4NlYyPzZ{MUm=
G401 MknBR4VtdCCYaXHibYxqfHliQYPzZZk> NVzWbVdtPTBibl2= MUWx5qCUPCCm NXrqZoNQTE2VT9Mg MYHy[YR2[2W|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MXyyOlE4PjJzOR?=
SK-NEP-1 MmPFRZBweHSxc3nzJGF{e2G7 MVe1NE8yODBibl2= M13s[FI1KGh? NI\3TZNFVVORwrC= M1TSbIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NH3DNGwzPjF5NkKxPS=>
G401 NV7S[HZVSXCxcITvd4l{KEG|c3H5 MVS1NE8yODBibl2= Moi3NlQhcA>? M2X0dGROW00EoB?= MYrpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVyyOlE4PjJzOR?=
SK-NEP-1 NEXHdVVHfW6ldHnvckBCe3OjeR?= MXW1NE8yODBibl2= Mlf2NlQhcA>? NXvvSpczTE2VT9Mg NFGwcGp{cG:5czD0bIUhcW6mdXP0bY9vKG:oIFTORUBnemGpbXXueIF1cW:w MoXxNlYyPzZ{MUm=
G401 MUjGeY5kfGmxbjDBd5NigQ>? M2nTW|UxNzFyMDDuUS=> MUmyOEBp MkLCSG1UV8Li NIPWV|R{cG:5czD0bIUhcW6mdXP0bY9vKG:oIFTORUBnemGpbXXueIF1cW:w MmfvNlYyPzZ{MUm=
SK-NEP-1 M3W5fGZ2dmO2aX;uJGF{e2G7 MUS1NE8yODBibl2= MWiyOEBp NYXYPJpETE2VT9Mg MWPpcoR2[2W|IHPlcIwh[3mlbHWg[Il{d3KmZYNCpC=> MXiyOlE4PjJzOR?=
G401 MkLzSpVv[3Srb36gRZN{[Xl? NFjsZoM2OC9zMECgcm0> NX3JWJRIOjRiaB?= MUjEUXNQyqB? Mn;nbY5lfWOnczDj[YxtKGO7Y3zlJIRqe2:{ZHXyxsA> MXGyOlE4PjJzOR?=
RPMI 8226 NFXIfXlE\WyuIGP1dpZqfmGuIFHzd4F6 MnjvNk81NzZibl2= NYL0VmZKPDkkgJno M3viR4lv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? MX[yOlAxODJ7Mh?=
OPM2 NHPwToZE\WyuIGP1dpZqfmGuIFHzd4F6 MlrnNk81NzZibl2= MkH5OFjjiImq NIXVOHFqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq MX[yOlAxODJ7Mh?=
U266 MVTD[YxtKFO3co\peoFtKEG|c3H5 NGTsfmMzNzRxNjDuUS=> NETYSY01QOLCiXi= NHnIRZdqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq NH3BbWUzPjByMEK5Ni=>
H929 NWPIW3IzS2WubDDTeZJ3cX[jbDDBd5NigQ>? MmHtNk81NzZibl2= NWrkeGl3PDkkgJno NXf5c2xNcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= NYLzd49GOjZyMECyPVI>
RPMI 8226  NEPGRmFCeG:ydH;zbZMhSXO|YYm= NWTIXVFPPOLCiX7N NWf5V2VJOjRxNEigbC=> NVvhXmk1cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NEK4TJIzPjByMEK5Ni=>
HCC827 NYfMfFlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\rc|lCOTBibl2= MV:0PEBp NH3BeGxFVVOR NXH1fY5[\W6qYX7j[ZMh[2m|cHzheIlvKHOnboPpeIl3cXS7wrC= NF\4WVYzPTl2NE[xOy=>
NCI-H23 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;sNVAhdk1? MnroOFghcA>? Mn62SG1UVw>? M2\JZoVvcGGwY3XzJINqe3CuYYTpckB{\W6|aYTpeol1gcLi NFjKe|AzPTl2NE[xOy=>
AML3 M2DBV2Z2dmO2aX;uJGF{e2G7 NWfR[5RPOC1zIN88US=> MkjMNlTDqGh? MXLpcoR2[2W|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1XjOFI2PjF{OUSx
ML-1 M3zTc2Z2dmO2aX;uJGF{e2G7 NGTBV|cxNTFizszN MYqyOOKhcA>? MkTSbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NVr0UFBUOjV4MUK5OFE>
RPMI-8226vr10  NULVOpVCTnWwY4Tpc44hSXO|YYm= MWewMVEh|ryP M17wWlI1yqCq NYK3OppycW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnOyNlU3OTJ7NEG=
ML-1 NVvxO3NuTnWwY4Tpc44hSXO|YYm= NXL2T4k{OSEQvF2= NUPneWlqOjUEoHi= M2PGVYlv[3KnYYPld{Bk[XOyYYPlMVMh[WO2aY\peJkhPC2ob3zk NYLjZY1COjV4MUK5OFE>
RPMI-8226vr10  NGnYbnZHfW6ldHnvckBCe3OjeR?= NV3KOoVvOSEQvF2= MmTPNlTDqGh? MoHVbY5kemWjc3XzJINie3Cjc3WtN{Bi[3Srdnn0fUAzNjVvZn;s[C=> M2X5e|I2PjF{OUSx
SK-N-BE (2) M4rSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrWPHkzPOLCiXi= M{m0bWlEPTB;MUC0MlDjiIoEsfMAjVcvQCCwTR?= M2XGcFI2OzB6OUG2
SK-N-BE (2), PAN  MK NYC3bIZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{G3RVI16oDLaB?= NEnTTIpKSzVyPUGwOE4x6oDLwsJihKk4Njhibl2= NX\we4VVOjV|MEi5NVY>
SK-N-BE (2), MK  PAN M3\sNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:0d|BCOjUkgJno M3\oRWlEPTB;M{iyMlDjiIoEsfMAjVQ{NjJibl2= NYW0enVLOjV|MEi5NVY>
SK-N-AS MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTvN|AzPOLCiXi= MlzBTWM2OD1|Nz6x5qCKyrIkgJmyMlQhdk1? NXLJcHNuOjV|MEi5NVY>
SK-N-DZ M3vqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jTPFI16oDLaB?= NX\1PW5uUUN3ME2xO{4y6oDLwsJihKkxNjRibl2= NUfEV2hJOjV|MEi5NVY>
Caki-1 MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDzNWkyOC9{NT:1NEBvVQ>? NHPwfmk1QCCq MmnYbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ MVSyOVI4QTF7MR?=
ACHN NFrGWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PD[FExNzJ3L{WwJI5O MnXYOFghcA>? NYP1O2tScW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny M3X4dFI2Ojd7MUmx
769-P NYixUXk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELrc|MyOC9{NT:1NEBvVQ>? M2DCOlQ5KGh? M1PyS4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= NFPacGQzPTJ5OUG5NS=>
786-O  NU\Y[HFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHQVWoyOC9{NT:1NEBvVQ>? MWG0PEBp NH3zTndqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= NU\GT4FyOjV{N{mxPVE>
Caki-1 MYLBdI9xfG:|aYOgRZN{[Xl? MV21NEBvVQ>? MY[0PEBp MWTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? NXvkUZBXOjV{N{mxPVE>
ACHN NHP4WplCeG:ydH;zbZMhSXO|YYm= MkHGOVAhdk1? NVq4VWZmPDhiaB?= Mny3bY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? M4[2flI2Ojd7MUmx
769-P M3;4XGFxd3C2b4Ppd{BCe3OjeR?= M4XaXFUxKG6P M3HFV|Q5KGh? NHTwNmVqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= MlXONlUzPzlzOUG=
786-O  MX\BdI9xfG:|aYOgRZN{[Xl? MmLGOVAhdk1? MmHUOFghcA>? MWHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? MXWyOVI4QTF7MR?=
Caki-1 NVLXPJpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHxO3QzPS93MDDuUS=> MoLhOFghcA>? MkG2SG1UVw>? NIOwNY1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni M1\HN|I2OTd4M{W0
ACHN NVjVb4tzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:ybYozPS93MDDuUS=> MmHXOFghcA>? MY\EUXNQ NYjDPHJZcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=> MVmyOVE4PjN3NB?=
769-P MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MniwNlUwPTBibl2= NWjMVFFTPDhiaB?= M1;E[WROW09? NVHoc3RMcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=> MXWyOVE4PjN3NB?=
Caki-1 MXfDc4xwdnliRn;ycYF1cW:wIFHzd4F6 MorlOVAhdk1? MYK3MVE1KGR? M1foWWROW09? MkHtd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> MWqyOVE4PjN3NB?=
ACHN NXXSe2p3S2:ub375JGZwem2jdHnvckBCe3OjeR?= NGfTfHE2OCCwTR?= MUO3MVE1KGR? MVnEUXNQ MnnBd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> MlnrNlUyPzZ|NUS=
769-P NYrpfZFUS2:ub375JGZwem2jdHnvckBCe3OjeR?= NXnKNW85PTBibl2= M1LiXVcuOTRiZB?= MljlSG1UVw>? NEPXWJF{fXCycnXzd4VlKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKHerdHigZo9zfGW8b33pZkDDqA>? MoCzNlUyPzZ|NUS=
Caki-1 NVT3Z3J4SXCxcITvd4l{KEG|c3H5 NVjCW5EzPTBibl2= NX\5dnZpPDhiaB?= NFP5ZVRFVVOR Mn:0bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MX6yOVE4PjN3NB?=
ACHN MkntRZBweHSxc3nzJGF{e2G7 MoTlOVAhdk1? NV;ySHdzPDhiaB?= MlzBSG1UVw>? NF\HeoFqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NXfOfVI3OjVzN{[zOVQ>
769-P NW\QR2pwSXCxcITvd4l{KEG|c3H5 NVLiTpB3PTBibl2= NH65ZYo1QCCq M1\i[2ROW09? M1u3bolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M17CWVI2OTd4M{W0
MDA-MB-231 NEW0O|hOd3KyaH;sc4dq[2GuIFPyfZN1[WxiVnnvcIV1KCiFVjmgRZN{[Xl? NW\QUHNmOTEEoH7N NWDreog6O8LiZB?= NGjOVI5FVVOR M2nFboFtfGW{czDj[YxtKG2xcoDoc4xw\3oEoB?= MV:yOFgyODR7Nx?=
BT-549 MXPNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk> MV[xNOKhdk1? M{LSbFPDqGR? NIH1N3RFVVOR Ml;tZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi MWiyOFgyODR7Nx?=
MCF-7  M3f0Xm1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? MWixNOKhdk1? MV[zxsBl M1HUbWROW09? Ml6wZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi MVWyOFgyODR7Nx?=
MCF-7 NH;lW|dHfW6ldHnvckBCe3OjeR?= NHPQdGE2NTVyIH7N NVr2R2hDOjRiaB?= NEjzVoFFVVOR NGe0R4Vz\WS3Y3XkJJRp\SCuZY\lcEBw\iCneIDy[ZN{cW:wIH;mJGVT|rFuIGDSJIFv\CCIb4jBNeKh Mn:wNlQ{PjZ2MEe=
CTS Mk[0RZBweHSxc3nzJGF{e2G7 MoTRNQKBmzRyIH7NxsA> MYG0PEBp MYnpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NGf6N4ozPDJ2NESyPS=>
OCI-AML3  MYfBdI9xfG:|aYOgRZN{[Xl? MofINQKBmzRyIH7NxsA> NELsUIU1QCCq M2K4RYlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MoPLNlQzPDR2Mkm=
U937 MWHBdI9xfG:|aYOgRZN{[Xl? MVmw5qCUPDBibl5CpC=> MWW0PEBp M3S3b4lv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NWDmNmNTOjR{NES0Nlk>
PC3 MV;BdI9xfG:|aYOgRZN{[Xl? M4C4cFAuOTByIH7N NUH2RWxROjRxNEigbC=> NYP6Z25McW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{DRVlI1OTZ|MkOw
PC3-AR MmroRZBweHSxc3nzJGF{e2G7 NXTYR2RFOC1zMECgcm0> NVjzXVZzOjRxNEigbC=> NH;GeHlqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MlHsNlQyPjN{M{C=
PC3 M4\4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf0NoYxNTFyMDDuUS=> NWrXVW5lOjRxNEigbC=> NXPFNXBmcW6mdXPld{Bi[2O3bYXsZZRqd25ib3[gd5VjTzFicH;weYxifGmxbh?= NELicHEzPDF4M{KzNC=>
PC3-AR NHfjUXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXlXG4xNTFyMDDuUS=> MoK3NlQwPDhiaB?= NInHeYhqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKHSqZTDHNm0heGijc3W= MUiyOFE3OzJ|MB?=
PC3 NVzSfld7TnWwY4Tpc44hSXO|YYm= MWCwMVExOCCwTR?= M1rFcVI1KGh? NHzje4Z{fXCycnXzd4V{KGW6cILld5Nqd25ib3[gZYN1cX[jdHXkJGFVVSxiQXv0JIFv\CCHcnuxM|IheHKxdHXpci=> MoWwNlQyPjN{M{C=
PC3-AR NF2xS25HfW6ldHnvckBCe3OjeR?= M{PHeFAuOTByIH7N NGfOeYYzPCCq MUXzeZBxemW|c3XzJIV5eHKnc4Ppc44hd2ZiYXP0bZZifGWmIFHUUUwhSWu2IHHu[EBGemtzL{KgdJJwfGWrbh?= MUWyOFE3OzJ|MB?=
OS-RC-2 NVK3c|JkS2WubDDWbYFjcWyrdImgRZN{[Xl? NULZbFVnOC1zMECwJI5O MVOyOE81QC95MjDo NVXkV486TE2VTx?= M1y5UIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFHmXo8zPDF2NEezOy=>
OS-RC-2 NYnwfopqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGWycVA2OCCwTR?= NV3KXWROPDhiaB?= Mn21SG1UVw>? MWnpcoR2[2W|IFeyM20h[XK{ZYP0 MWiyOFE1PDd|Nx?=
OS-RC-2 NVvBZmJVSXCxcITvd4l{KEG|c3H5 MUm1NEBvVQ>? NUO3WotIPDhiaB?= MlmzSG1UVw>? M4\kV4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NF3ieFczPDF2NEezOy=>
SK-N-AS NHv0OXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[3W5kx6oDVOECgcm0> NVrld4d5PDhiaB?= M2Pje2lEPTB;MkeuOEBvVQ>? MkfwNlQxQTh5OUm=
SK-N-DZ NHOzOmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M376TVDjiJN6MDDuUS=> MXe0PEBp NFT0O2ZKSzVyPUKxMlkhdk1? NULNfIV{OjRyOUi3PVk>
SK-N-SH M2LQVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M374WFDjiJN6MDDuUS=> NEHYUXk1QCCq NYD5U5NOUUN3ME23Nk4{KG6P M2HTVVI1ODl6N{m5
SK-N-BE NV\NZ4hDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DrTFDjiJN6MDDuUS=> NEPzSFY1QCCq MXPJR|UxRTd3LkSgcm0> MUmyOFA6QDd7OR?=
SK-N-AS MnHjRZBweHSxc3nzJGF{e2G7 MVyw5qCUQDBibl2= MojqOFghcA>? NXn4eId[eG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v NV[2UYFnOjRyOUi3PVk>
SK-N-DZ NI\a[ndCeG:ydH;zbZMhSXO|YYm= MkDHNQKBmzhyIH7N MXm0PEBp MVrwc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36= M3PwTVI1ODl6N{m5
SK-N-SH NXX2NVNSSXCxcITvd4l{KEG|c3H5 M3ezZVDjiJN2MDDuUS=> M1vuR|Q5KGh? NFOzdZFxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> M4PEbVI1ODl6N{m5
SK-N-BE M{T2b2Fxd3C2b4Ppd{BCe3OjeR?= MX6w5qCUPDBibl2= M4\HSFQ5KGh? MYXwc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36= MUCyOFA6QDd7OR?=
SK-N-AS NEHJSY5HfW6ldHnvckBCe3OjeR?= M3W2fFDjiJN6MDDuUS=> M{fHN|Q5KGh? MVrpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ M1vPXFI1ODl6N{m5
SK-N-DZ M2X2ZmZ2dmO2aX;uJGF{e2G7 MVSw5qCUQDBibl2= MXK0PEBp NH7OR3RqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[UA{KGGwZDDQRXJR MX:yOFA6QDd7OR?=
SK-N-SH MWTGeY5kfGmxbjDBd5NigQ>? M3SzSlDjiJN2MDDuUS=> MUe0PEBp MVLpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ MoTFNlQxQTh5OUm=
SK-N-BE NW\WWWxoTnWwY4Tpc44hSXO|YYm= NULz[Io6OOLCk{SwJI5O NH;FWnA1QCCq MVHpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ MYCyOFA6QDd7OR?=
HCC-LM3 M4HneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M161bVEuOTByMDDuUS=> MYCyOE81QC95MjDo Moq4SG1UVw>? M{\F[4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NGntU5AzPDB7M{m1Oi=>
HepG2 MkKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrKRXVsOS1zMECwJI5O M3LUflI1NzR6L{eyJIg> MXXEUXNQ NUHZdHUxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NV;B[npTOjRyOUO5OVY>
SMMC-7721 MnrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPhR5RlOS1zMECwJI5O NHHQcpAzPC92OD:3NkBp NEnUfGVFVVOR NFrMcoxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MU[yOFA6Ozl3Nh?=
HCC-LM3 M3LuSWFxd3C2b4Ppd{BCe3OjeR?= NWPHTYJIPTBibl2= NYHYXnZFPDhiaB?= NYniflRTTE2VTx?= MkjsbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk> MUiyOFA6Ozl3Nh?=
HepG2 NHvXdXBCeG:ydH;zbZMhSXO|YYm= NITseFk2OCCwTR?= M4DpeVQ5KGh? MXzEUXNQ M2DrO4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 NUDzN2M3OjRyOUO5OVY>
SMMC-7721 MmnrRZBweHSxc3nzJGF{e2G7 MVW1NEBvVQ>? NXHRb3p7PDhiaB?= M{m0OmROW09? NHyz[4lqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMhOyxiODDhcoQhQQ>? M4\rXVI1ODl|OUW2
HCC-LM3 MmX2SpVv[3Srb36gRZN{[Xl? M1LIWFUxNzFyMDDuUS=> MV:yOEBp MmLTSG1UVw>? MX\k[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyLWPURXQ{KGGwZDDwMWFsfMLi MUWyOFA6Ozl3Nh?=
HepG2 MkS0SpVv[3Srb36gRZN{[Xl? MVy1NE8yODBibl2= MofwNlQhcA>? NUf3RZU1TE2VTx?= NVzrTVc6\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> M1zyU|I1ODl|OUW2
SMMC-7721 NWXFWmplTnWwY4Tpc44hSXO|YYm= NEfoT|g2OC9zMECgcm0> MlvFNlQhcA>? NWXtN3h1TE2VTx?= M{PGXYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC= Mo\kNlQxQTN7NU[=
HCC-LM3 NFfG[YtHfW6ldHnvckBCe3OjeR?= MWe1NE8yODBibl2= MX[yOEBp NUDnRXpDTE2VTx?= MV\kc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v Mom0NlQxQTN7NU[=
HepG2 NG\RXVJHfW6ldHnvckBCe3OjeR?= MXG1NE8yODBibl2= NH\6WnozPCCq NXj1NII1TE2VTx?= NYr5ToVO\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= NFzofoEzPDB7M{m1Oi=>
SMMC-7721 NEiwRW9HfW6ldHnvckBCe3OjeR?= NG\h[3A2OC9zMECgcm0> MUKyOEBp NWfjcmlFTE2VTx?= NWDadoFj\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= NHvKdZEzPDB7M{m1Oi=>
FaDu MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDXe2hzOTBy4pEFcm0> MXS4M|ExNzF{IHi= MX3kbZNxdGG7ZXSgZUB{cWewaX\pZ4FvfCCjbnSgdJJwdG:wZ3XkJGczN01iYYLy[ZN1KGG2IEigZY5lKDF{4pEFbEBxd3O2IILlcIVie2V? M{m1PFI1ODJ4NEiy
FaDu MXTGeY5kfGmxbjDBd5NigQ>? M17aWFExOOLChX7N MV:yM|QwQC9zMjDo MUHpcoR2[2WmIICyNXdi\jFxQ3nwNeKh\XiycnXzd4lwdg>? NWPlXIlIOjRyMk[0PFI>
PC-3  MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXSxOI9EOC1zMDFOwG0> NUSxbnM3OjRxNEivO|IhcA>? NFrqRVBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MYWyN|k6OTJzNh?=
LNCaP MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn6R49COC13IN88US=> M3rTclI1NzR6L{eyJIg> MljMbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2SwcFI{QTlzMkG2
RWPE-1  Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLXeZBFOC1{MDFOwG0> M{\oPVI1NzR6L{eyJIg> MVHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MV2yN|k6OTJzNh?=
Capan-1 MnLXSpVv[3Srb36gRZN{[Xl? MkLiNlUwPTBxMUCwJI5O NXfxZlJCQC9{ND:0PEBp NHK4fI1FVVOR Ml\X[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?= NWfZU4xGOjN7MkK4PFY>
L3.6pl MXXGeY5kfGmxbjDBd5NigQ>? NUD0UYJ3OjVxNUCvNVAxKG6P NVnKWWo5QC9{ND:0PEBp MVfEUXNQ NISxSW9ld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n NH\MXnczOzl{Mki4Oi=>
CFPAC-1  M13DPWZ2dmO2aX;uJGF{e2G7 MmTLNlUwPTBxMUCwJI5O NIS5cZA5NzJ2L{S4JIg> NFfDS5JFVVOR MlvP[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?= MUCyN|kzOjh6Nh?=
Capan-1 NULyRoZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYOyOU82OC9zMECgcm0> Mnj2OFghcA>? NGHCe4lFVVOR NFSxU|Nz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVfVdmd7OjN7MkK4PFY>
L3.6pl NUX1[45zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUWyOU82OC9zMECgcm0> NHq4TlE1QCCq MVjEUXNQ NH[3Oppz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MoK1NlM6OjJ6OE[=
CFPAC-1  NGO0SYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXSyOU82OC9zMECgcm0> MU[0PEBp M{HaXWROW09? M3K0e5Jm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NVn1em1pOjN7MkK4PFY>
Capan-1 MV;BdI9xfG:|aYOgRZN{[Xl? NYTue41vOjVxNUCvNVAxKG6P MnzGOFghcA>? NHHmUWhFVVOR NHnmR|NqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MWeyN|kzOjh6Nh?=
L3.6pl NHL5cXRCeG:ydH;zbZMhSXO|YYm= NV;UNZpQOjVxNUCvNVAxKG6P M4TJ[lQ5KGh? NWD5cXlZTE2VTx?= NYPmdI1lcW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NXXLTolTOjN7MkK4PFY>
CFPAC-1  NWLFWZNrSXCxcITvd4l{KEG|c3H5 NETDcFAzPS93MD:xNFAhdk1? NYPVNmExPDhiaB?= MWDEUXNQ MnWzbY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MmnONlM6OjJ6OE[=
HN22 NEjwTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPNTJcxNTJyIH7N Ml3DNlQwPDhiaB?= NGPB[2JFVVOR NIqyTmdqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz MoDyNlM5Pzd{M{W=
HSC4  NE\PUXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjkZ3ExNTJyIH7N M4PHZ|I1NzR6IHi= NHq5U5VFVVOR NH\vbHpqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz M3vBNFI{QDd5MkO1
HN22 MmTzRZBweHSxc3nzJGF{e2G7 MYKwMVIxKG6P MljpOFghcA>? NFzTWYdFVVOR MkC3bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MofoNlM5Pzd{M{W=
HSC4  Mn\RRZBweHSxc3nzJGF{e2G7 NUDYN4NNOC1{MDDuUS=> NUnQb2dLPDhiaB?= MXXEUXNQ NE\rNnFqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MoPWNlM5Pzd{M{W=
HN22 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmryNE0zOCCwTR?= MnLQOFghcA>? MYXEUXNQ NGToZ|NqdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0xsA> MlfFNlM5Pzd{M{W=
HSC4  NGG4U4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr0WWhjOC1{MDDuUS=> NV3vS2VpPDhiaB?= M3vOSGROW09? M37yfolv\HWlZYOgS|EheGijc3WgZ4VtdCCleXPs[UBienKnc4VCpC=> MXqyN|g4PzJ|NR?=
HN22 MV\GeY5kfGmxbjDBd5NigQ>? M3W0OFAuOjBibl2= MVO0PEBp M3zFe2ROW09? NGDjXoR{fXCycnXzd4V{KFOyMTDlfJBz\XO|aX;uxsA> M{LPUVI{QDd5MkO1
HSC4  MVLGeY5kfGmxbjDBd5NigQ>? Ml\nNE0zOCCwTR?= NGLVUIE1QCCq MnXGSG1UVw>? NGjR[WN{fXCycnXzd4V{KFOyMTDlfJBz\XO|aX;uxsA> MV6yN|g4PzJ|NR?=
Cal62 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfoTWM2OD1|MzFCtUA1KG6P M3PnXlI{QDJ2ME[0
Hth7 NHn0TFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\PO2lEPTB;MUWgxtEhOiCwTR?= MYOyN|gzPDB4NB?=
Hth83 M3;6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTN2INMxJFUhdk1? Mn\ENlM5OjRyNkS=
C643 NWq1V3M6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXsTWM2OD15MTFCtUAyOCCwTR?= NYm0e2RbOjN6MkSwOlQ>
SW1736 NXzBdY82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTN3INMxJFghdk1? NFr3U3czOzh{NEC2OC=>
T241 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfVUHRrUUN3ME22OUDDuSB5IH7N M2rFeFI{QDJ2ME[0
T351 NFHFc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3n0WmlEPTB;NUCgxtEhOTBibl2= NIrSSXIzOzh{NEC2OC=>
BHP2-7 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTN5INMxJFYhdk1? M3jucFI{QDJ2ME[0
T238 Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFuNUCwJOKyKDJyMDDuUS=> Mm\CNlM5OjRyNkS=
HCT8 M{TNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fJcVczKGh? NV7QN3lmTE2VTx?= M2Pkb2lEPTB;MUKuPgKBkcLz4pEJNU46KG6P NUHVNlQyOjN{OUmzPFg>
H630 NHXCN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWq3NkBp MVHEUXNQ M1ToUmlEPTB;MUKuOQKBkcLz4pEJN{4yKG6P NXvkPWFiOjN{OUmzPFg>
cH630 5-FU-res MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjwSGY4OiCq M4rDd2ROW09? MkjvTWM2OD1zNT615qCKyrIkgJmxMlIhdk1? MXOyN|I6QTN6OB?=
HCT116 M1\wc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYm3NkBp NGjWRZBFVVOR MWfJR|UxRTFyLkhihKnDueLCiUKuNkBvVQ>? MlTLNlMzQTl|OEi=
HCT116 p53−/− NULp[4pGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWO3NkBp M160TmROW09? MV;JR|UxRThwNvMAjeKy6oDLMT63JI5O NUe3VWdvOjN{OUmzPFg>
dHCT116 p21−/− M2XCe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTp[IU4OiCq M4nDXGROW09? NETUZlZKSzVyPUWuPgKBkcLz4pEJNU4{KG6P M3[1e|I{Ojl7M{i4
HT29 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojBO|IhcA>? M4f6WWROW09? NFfMVlhKSzVyPUG2MlPjiIoEsfMAjVIvOyCwTR?= NUO1V4xUOjN{OUmzPFg>
LoVo M2njWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2SwZVczKGh? M3vz[2ROW09? MXXJR|UxRTVwMfMAjeKy6oDLMD62JI5O MV[yN|I6QTN6OB?=
RKO MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjPfFI4OiCq M2TiUmROW09? M1fHR2lEPTB;Nz655qCKyrIkgJmyMlIhdk1? NGTte48zOzJ7OUO4PC=>
SW480 M{fjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{K2SVczKGh? NH20SVNFVVOR NGHRbZdKSzVyPUG3MlXjiIoEsfMAjVAvQCCwTR?= NWD3RppQOjN{OUmzPFg>
eSW620 NFHp[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\BO|IhcA>? MojlSG1UVw>? NFuxfVlKSzVyPUmuNgKBkcLz4pEJNk4yKG6P NVjQR5NKOjN{OUmzPFg>

... Click to View More Cell Line Experimental Data

In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Formulation: Dextrose 5% in water
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
Synonyms NVP-LBH589

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02802163 Not yet recruiting Multiple Myeloma H. Lee Moffitt Cancer Center and Research Institute|Novartis|Amgen April 30, 2017 Phase 1|Phase 2
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT02890069 Recruiting Colorectal Cancer|Non-small Cell Lung Carcinoma (Adenocarcinoma)|Triple Negative Breast Cancer Novartis Pharmaceuticals|Novartis October 26, 2016 Phase 1
NCT01802879 Active, not recruiting Hematologic Neoplasms Novartis Pharmaceuticals|Novartis June 24, 2013 Phase 2
NCT00532675 Active, not recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 22, 2008 Phase 1
NCT02961816 Not yet recruiting Lymphoma M.D. Anderson Cancer Center February 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID